---
document_datetime: 2025-12-02 04:57:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat-siga.html
document_name: tecovirimat-siga.html
version: success
processing_time: 0.1050535
conversion_datetime: 2025-12-27 23:28:13.376366
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tecovirimat SIGA

[RSS](/en/individual-human-medicine.xml/67513)

##### Authorised

This medicine is authorised for use in the European Union

tecovirimat monohydrate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tecovirimat SIGA](#news-on)
- [More information on Tecovirimat SIGA](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tecovirimat SIGA is a medicine to treat smallpox, monkeypox and cowpox, three infections caused by viruses belonging to the same family (orthopoxviruses). It is also used to treat complications that can happen following vaccination against smallpox. Tecovirimat SIGA is used in adults and children weighing at least 13 kg.

It contains the active substance tecovirimat.

Expand section

Collapse section

## How is Tecovirimat SIGA used?

The medicine can only be obtained with a prescription.

Tecovirimat SIGA is available as capsules to be taken by mouth, and the dose depends on bodyweight. Tecovirimat treatment should be initiated as soon as possible after diagnosis.

For more information about using Tecovirimat SIGA, see the package leaflet or contact your doctor or pharmacist.

## How does Tecovirimat SIGA work?

Tecovirimat SIGA works by interfering with a protein called VP37 that is found on the surface of orthopoxviruses, including smallpox, monkeypox and cowpox. By interacting with this protein, the medicine prevents the viruses from reproducing normally, slowing down the spread of infection.

## What benefits of Tecovirimat SIGA have been shown in studies?

Because smallpox, monkeypox and cowpox are either eradicated (smallpox) or occur sporadically in the EU, studies to assess the effectiveness of Tecovirimat SIGA in infected people could not be carried out.

The effectiveness of Tecovirimat SIGA was therefore evaluated based on studies in animals infected with lethal doses of orthopoxviruses, on studies on the medicine's effects in the human body, and on the way the medicine is absorbed, modified and removed from the body in humans and animals (pharmacodynamics and pharmacokinetics studies).

Studies in animals who had received lethal doses of either monkeypox or rabbitpox viruses showed that treatment with Tecovirimat SIGA for 14 days significantly increased survival rates: when treatment started either 4 or 5 days after infection, between 80 and 100% of the animals that were treated with Tecovirimat SIGA survived. No animals in the placebo groups survived. The survival rate was 50% when treatment started 6 days after the infection.

The dose that is needed in humans to ensure that Tecovirimat SIGA will work as expected was determined based on comparative pharmacokinetics and pharmacodynamics studies carried out in animals and in humans.

## What are the risks associated with Tecovirimat SIGA?

The most common side effects with Tecovirimat SIGA are headache (which may affect more than 1 in 10 people) and nausea (feeling sick) (which may affect up to 1 in 10 people).

For the full list of restrictions, see the package leaflet.

## Why is Tecovirimat SIGA authorised in the EU?

The European Medicines Agency considered that Tecovirimat SIGA is effective at reducing mortality caused by smallpox, monkeypox and cowpox, based on animal studies. While the safety of the medicine was assessed in non-infected people, the side effects of Tecovirimat SIGA are expected to be similar in infected people and are considered acceptable. The European Medicines Agency therefore decided that Tecovirimat SIGA's benefits are greater than its risks and it can be authorised for use in the EU.

There are no other treatments authorised for the monkeypox and cowpox infections, which although rare can be fatal. In addition, while smallpox has been eradicated, this is an extremely serious infection, for which no treatment exists should an outbreak occur.

Tecovirimat SIGA has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Tecovirimat SIGA due to the rarity of the diseases. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Tecovirimat SIGA?

Since Tecovirimat SIGA has been authorised under exceptional circumstances, the company that markets Tecovirimat SIGA will provide data on the effectiveness and safety of the medicine in patients given the medicine should an outbreak of smallpox occur.

## What measures are being taken to ensure the safe and effective use of Tecovirimat SIGA?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tecovirimat SIGA have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tecovirimat SIGA are continuously monitored. Suspected side effects reported with Tecovirimat SIGA are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tecovirimat SIGA

Tecovirimat SIGA received a marketing authorisation valid throughout the EU on 06 January 2022.

Tecovirimat SIGA : EPAR - Medicine Overview

Reference Number: EMA/44982/2022

English (EN) (96.05 KB - PDF)

**First published:** 28/01/2022

[View](/en/documents/overview/tecovirimat-siga-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-228)

български (BG) (122.76 KB - PDF)

**First published:**

28/01/2022

[View](/bg/documents/overview/tecovirimat-siga-epar-medicine-overview_bg.pdf)

español (ES) (96.79 KB - PDF)

**First published:**

28/01/2022

[View](/es/documents/overview/tecovirimat-siga-epar-medicine-overview_es.pdf)

čeština (CS) (119.49 KB - PDF)

**First published:**

28/01/2022

[View](/cs/documents/overview/tecovirimat-siga-epar-medicine-overview_cs.pdf)

dansk (DA) (97.13 KB - PDF)

**First published:**

28/01/2022

[View](/da/documents/overview/tecovirimat-siga-epar-medicine-overview_da.pdf)

Deutsch (DE) (100.51 KB - PDF)

**First published:**

28/01/2022

[View](/de/documents/overview/tecovirimat-siga-epar-medicine-overview_de.pdf)

eesti keel (ET) (83.54 KB - PDF)

**First published:**

28/01/2022

[View](/et/documents/overview/tecovirimat-siga-epar-medicine-overview_et.pdf)

ελληνικά (EL) (123.79 KB - PDF)

**First published:**

28/01/2022

[View](/el/documents/overview/tecovirimat-siga-epar-medicine-overview_el.pdf)

français (FR) (97.84 KB - PDF)

**First published:**

28/01/2022

[View](/fr/documents/overview/tecovirimat-siga-epar-medicine-overview_fr.pdf)

hrvatski (HR) (117.69 KB - PDF)

**First published:**

28/01/2022

[View](/hr/documents/overview/tecovirimat-siga-epar-medicine-overview_hr.pdf)

italiano (IT) (95.48 KB - PDF)

**First published:**

28/01/2022

[View](/it/documents/overview/tecovirimat-siga-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (127.45 KB - PDF)

**First published:**

28/01/2022

[View](/lv/documents/overview/tecovirimat-siga-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (117.9 KB - PDF)

**First published:**

28/01/2022

[View](/lt/documents/overview/tecovirimat-siga-epar-medicine-overview_lt.pdf)

magyar (HU) (117.56 KB - PDF)

**First published:**

28/01/2022

[View](/hu/documents/overview/tecovirimat-siga-epar-medicine-overview_hu.pdf)

Malti (MT) (120.63 KB - PDF)

**First published:**

28/01/2022

[View](/mt/documents/overview/tecovirimat-siga-epar-medicine-overview_mt.pdf)

Nederlands (NL) (97.66 KB - PDF)

**First published:**

28/01/2022

[View](/nl/documents/overview/tecovirimat-siga-epar-medicine-overview_nl.pdf)

polski (PL) (121.91 KB - PDF)

**First published:**

28/01/2022

[View](/pl/documents/overview/tecovirimat-siga-epar-medicine-overview_pl.pdf)

português (PT) (97.03 KB - PDF)

**First published:**

28/01/2022

[View](/pt/documents/overview/tecovirimat-siga-epar-medicine-overview_pt.pdf)

română (RO) (116.02 KB - PDF)

**First published:**

28/01/2022

[View](/ro/documents/overview/tecovirimat-siga-epar-medicine-overview_ro.pdf)

slovenčina (SK) (118.11 KB - PDF)

**First published:**

28/01/2022

[View](/sk/documents/overview/tecovirimat-siga-epar-medicine-overview_sk.pdf)

slovenščina (SL) (116.59 KB - PDF)

**First published:**

28/01/2022

[View](/sl/documents/overview/tecovirimat-siga-epar-medicine-overview_sl.pdf)

Suomi (FI) (94.15 KB - PDF)

**First published:**

28/01/2022

[View](/fi/documents/overview/tecovirimat-siga-epar-medicine-overview_fi.pdf)

svenska (SV) (95.32 KB - PDF)

**First published:**

28/01/2022

[View](/sv/documents/overview/tecovirimat-siga-epar-medicine-overview_sv.pdf)

Tecovirimat SIGA - EPAR - Risk management plan

English (EN) (567.53 KB - PDF)

**First published:** 28/01/2022

**Last updated:** 10/11/2025

[View](/en/documents/rmp/tecovirimat-siga-epar-risk-management-plan_en.pdf)

## Product information

Tecovirimat SIGA : EPAR - Product Information

English (EN) (380.33 KB - PDF)

**First published:** 28/01/2022

**Last updated:** 10/11/2025

[View](/en/documents/product-information/tecovirimat-siga-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-369)

български (BG) (499.09 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/bg/documents/product-information/tecovirimat-siga-epar-product-information_bg.pdf)

español (ES) (377.82 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/es/documents/product-information/tecovirimat-siga-epar-product-information_es.pdf)

čeština (CS) (433.53 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/cs/documents/product-information/tecovirimat-siga-epar-product-information_cs.pdf)

dansk (DA) (409.92 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/da/documents/product-information/tecovirimat-siga-epar-product-information_da.pdf)

Deutsch (DE) (408.85 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/de/documents/product-information/tecovirimat-siga-epar-product-information_de.pdf)

eesti keel (ET) (372.75 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/et/documents/product-information/tecovirimat-siga-epar-product-information_et.pdf)

ελληνικά (EL) (549.94 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/el/documents/product-information/tecovirimat-siga-epar-product-information_el.pdf)

français (FR) (436.44 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/fr/documents/product-information/tecovirimat-siga-epar-product-information_fr.pdf)

hrvatski (HR) (439.44 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/hr/documents/product-information/tecovirimat-siga-epar-product-information_hr.pdf)

íslenska (IS) (415.2 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/is/documents/product-information/tecovirimat-siga-epar-product-information_is.pdf)

italiano (IT) (396.09 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/it/documents/product-information/tecovirimat-siga-epar-product-information_it.pdf)

latviešu valoda (LV) (433.3 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/lv/documents/product-information/tecovirimat-siga-epar-product-information_lv.pdf)

lietuvių kalba (LT) (446.27 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/lt/documents/product-information/tecovirimat-siga-epar-product-information_lt.pdf)

magyar (HU) (467.75 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/hu/documents/product-information/tecovirimat-siga-epar-product-information_hu.pdf)

Malti (MT) (464.64 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/mt/documents/product-information/tecovirimat-siga-epar-product-information_mt.pdf)

Nederlands (NL) (380.35 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/nl/documents/product-information/tecovirimat-siga-epar-product-information_nl.pdf)

norsk (NO) (391.38 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/no/documents/product-information/tecovirimat-siga-epar-product-information_no.pdf)

polski (PL) (452.9 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/pl/documents/product-information/tecovirimat-siga-epar-product-information_pl.pdf)

português (PT) (421.42 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/pt/documents/product-information/tecovirimat-siga-epar-product-information_pt.pdf)

română (RO) (467.06 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/ro/documents/product-information/tecovirimat-siga-epar-product-information_ro.pdf)

slovenčina (SK) (466.64 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/sk/documents/product-information/tecovirimat-siga-epar-product-information_sk.pdf)

slovenščina (SL) (454.75 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/sl/documents/product-information/tecovirimat-siga-epar-product-information_sl.pdf)

Suomi (FI) (390.33 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/fi/documents/product-information/tecovirimat-siga-epar-product-information_fi.pdf)

svenska (SV) (391.38 KB - PDF)

**First published:**

28/01/2022

**Last updated:**

10/11/2025

[View](/sv/documents/product-information/tecovirimat-siga-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000244868 02/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tecovirimat SIGA : EPAR - All authorised presentations

English (EN) (96.44 KB - PDF)

**First published:** 28/01/2022

[View](/en/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-552)

български (BG) (113.21 KB - PDF)

**First published:**

28/01/2022

[View](/bg/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.83 KB - PDF)

**First published:**

28/01/2022

[View](/es/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_es.pdf)

čeština (CS) (115.24 KB - PDF)

**First published:**

28/01/2022

[View](/cs/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (98.51 KB - PDF)

**First published:**

28/01/2022

[View](/da/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (100.82 KB - PDF)

**First published:**

28/01/2022

[View](/de/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.91 KB - PDF)

**First published:**

28/01/2022

[View](/et/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (128.01 KB - PDF)

**First published:**

28/01/2022

[View](/el/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_el.pdf)

français (FR) (95.06 KB - PDF)

**First published:**

28/01/2022

[View](/fr/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (114.69 KB - PDF)

**First published:**

28/01/2022

[View](/hr/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (95.53 KB - PDF)

**First published:**

28/01/2022

[View](/is/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_is.pdf)

italiano (IT) (97.63 KB - PDF)

**First published:**

28/01/2022

[View](/it/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (140.06 KB - PDF)

**First published:**

28/01/2022

[View](/lv/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (138.81 KB - PDF)

**First published:**

28/01/2022

[View](/lt/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (117.61 KB - PDF)

**First published:**

28/01/2022

[View](/hu/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (132.86 KB - PDF)

**First published:**

28/01/2022

[View](/mt/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (114.46 KB - PDF)

**First published:**

28/01/2022

[View](/nl/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (97.79 KB - PDF)

**First published:**

28/01/2022

[View](/no/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_no.pdf)

polski (PL) (85.73 KB - PDF)

**First published:**

28/01/2022

[View](/pl/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_pl.pdf)

português (PT) (68.06 KB - PDF)

**First published:**

28/01/2022

[View](/pt/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_pt.pdf)

română (RO) (83.35 KB - PDF)

**First published:**

28/01/2022

[View](/ro/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (137.37 KB - PDF)

**First published:**

28/01/2022

[View](/sk/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (51.82 KB - PDF)

**First published:**

28/01/2022

[View](/sl/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (94.61 KB - PDF)

**First published:**

28/01/2022

[View](/fi/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (20.32 KB - PDF)

**First published:**

28/01/2022

[View](/sv/documents/all-authorised-presentations/tecovirimat-siga-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tecovirimat SIGA Active substance tecovirimat International non-proprietary name (INN) or common name tecovirimat monohydrate Therapeutic area (MeSH)

- Poxviridae Infections
- Cowpox
- Monkeypox
- Vaccinia
- Smallpox

Anatomical therapeutic chemical (ATC) code J05AX24

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:

- Smallpox
- Monkeypox
- Cowpox

Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1).

Tecovirimat SIGA should be used in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/005248

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

SIGA Technologies Netherlands B.V.

Prinsenhil 29

Opinion adopted 11/11/2021 Marketing authorisation issued 06/01/2022 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tecovirimat SIGA : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (166.36 KB - PDF)

**First published:** 29/03/2023

**Last updated:** 10/11/2025

[View](/en/documents/procedural-steps-after/tecovirimat-siga-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tecovirimat SIGA-H-C-PSUSA-00010971-202401 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/539162/2024

English (EN) (178.68 KB - PDF)

**First published:** 22/11/2024

[View](/en/documents/scientific-conclusion/tecovirimat-siga-h-c-psusa-00010971-202401-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Tecovirimat SIGA : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/703119/2021

English (EN) (7.02 MB - PDF)

**First published:** 28/01/2022

[View](/en/documents/assessment-report/tecovirimat-siga-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Tecovirimat SIGA

Adopted

Reference Number: EMA/CHMP/606390/2021

English (EN) (107.25 KB - PDF)

**First published:** 12/11/2021

[View](/en/documents/smop-initial/chmp-summary-opinion-tecovirimat-siga_en.pdf)

#### News on Tecovirimat SIGA

[EMA response to the monkeypox public health emergency](/en/news/ema-response-monkeypox-public-health-emergency) 27/07/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

#### More information on Tecovirimat SIGA

- [Tecovirimat SIGA - referral](/en/medicines/human/referrals/tecovirimat-siga)

**This page was last updated on** 10/11/2025

## Share this page

[Back to top](#main-content)